Although our study didn’t confirm the association between TGF-β receptor inhibitor and the migration of endometrial cancer cells in vivo, the results showed that ISL reduced the expression of TGFβ serum levels, expression levels of p-Smad2 and TWIST1/2 as well as downstream target markers in vivo, thus we propose that ISL may reduce HEC-1A cells migration via TGFβ signaling. This evidence concerns the gene TGFB1 and endometrial cancer.